Clay Siegall founded Seattle Genetics in 1998, and the company has been working with major drug manufacturers ever since. The company began as a small effort but is now a much larger company that is known for its cancer therapies. Seigall believes that chemotherapy will soon become a treatment of the past for cancer and that targeted therapies will serve as the future. He has always been interested in medicine and loves working on therapies that extend people’s lives beyond their expectations. His interest in treating cancer began when a family member got the disease and became extremely ill from the chemotherapy. After this incident, he began to look into other treatments and eventually decided that he wanted to be the one creating new therapies that targeted cancer.
Clay Seigall revealed, in an interview, that there was a time when things got rough for his company. In response, he buckled down and worked harder than he ever had before. His work ethic was a large part of what got his company through that rough patch, and he has never looked back since. He is looking forward to being a part of the future of antibody-based therapies that help to treat cancer.
Clay Siegall is the cofounder, President, Chief Executive Officer, and Chairman on the Board of Directors for Seattle Genetics. The company has been working to successfully create a spread of cancer therapies that are antibody-based, and one of their most well-known products is ADCETRIS, which was approved by the FDA. Siegall has his hand in quite a bit of what his business does and has also been a large part of raising capital and funds for it.
Clay Siegall started out his earlier life by attending the University of Maryland where he earned a Bachelor’s of Science degree in Zoology. He decided to continue his education at George Washington University and came away from there with a Ph.D. in Genetics. Before he started up Seattle Genetics, he worked with the Bristol-Meyers Squibb Pharmaceutical Research Institute. He also spent some time working with the National Institutes of Health as well as the National Cancer Institute. Today, he sits on the Board of Directors for Alder BioPharmaceuticals and continues to grow his company as its leader.